A pilot study of bevacizumab and interferon-α2b in ocular melanoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 1, 2011, Pages 87-91

  Guenterberg, Kristan D ^a   Grignol, Valerie P ^a   Relekar, Kiran V ^a   Varker, Kimberly A ^a   Chen, Helen X ^b   Kendra, Kari L ^a   Olencki, Thomas E ^a   Carson, William E ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

angiogenic factor; bevacizumab; interferon alpha2b; uveal neoplasm; vascular endothelial growth factor

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; FIBRINOGEN; FUROSEMIDE; PROTEIN S; RECOMBINANT ALPHA2B INTERFERON; TEMOZOLOMIDE; THALIDOMIDE;

ADULT; AGED; ANOREXIA; ANXIETY; ARTERY THROMBOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SIZE; CHILL; CLINICAL ARTICLE; CONSTIPATION; DEHYDRATION; DEPRESSION; DIAPHORESIS; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPEPSIA; DYSPNEA; EYE CANCER; EYE MELANOMA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GRANULOCYTE; HEADACHE; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTE; LIVER METASTASIS; LUNG METASTASIS; LYMPHOCYTOPENIA; MALE; MELANOMA; METASTASIS; MOOD CHANGE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PROTEINURIA; PROTHROMBIN TIME; RIGOR; SIDE EFFECT; TASTE DISORDER; THROMBOEMBOLISM; TREATMENT DURATION; VOMITING; WEIGHT REDUCTION;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EYE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON ALFA-2B; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PILOT PROJECTS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79951676880     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181d2ed67     Document Type: Article

References (42)

1. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1998;83:1664-1678. (Pubitemid 28465486)
2. Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am. 2005;18:75-84, viii. (Pubitemid 40348812)
3. Srivastava A, Ralhan R, Kaur J. Angiogenesis in cutaneous melanoma: pathogenesis and clinical implications. Microsc Res Tech. 2003;60:208-224. (Pubitemid 36125709)
4. Graeven U, Rodeck U, Karpinski S, et al. Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res. 2001;61:7282-7290. (Pubitemid 32946527)
5. Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol. 1995;129:895-898.
6. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676. (Pubitemid 36749215)
7. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358:2039-2049. (Pubitemid 351656458)
8. Parangi S, O'Reilly M, Christofori G, et al. Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci U S A. 1996;93:2002-2007. (Pubitemid 26079871)
9. Danson S, Lorigan P. Improving outcomes in advanced malignant melanoma: update on systemic therapy. Drugs. 2005;65:733-743. (Pubitemid 40593623)
10. Rosenblatt MI, Azar DT. Anti-angiogenic therapy: prospects for treatment of ocular tumors. Semin Ophthalmol. 2006;21:151-160. (Pubitemid 44266789)
11. Tapper D, Langer R, Bellows AR, et al. Angiogenesis capacity as a diagnostic marker for human eye tumors. Surgery. 1979;86:36-40. (Pubitemid 10211201)
12. Boyd SR, Tan D, Bunce C, et al. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol. 2002;86:448-452. (Pubitemid 34293296)
13. Ijland SA, Jager MJ, Heijdra BM, et al. Expression of angiogenic and immunosuppressive factors by uveal melanoma cell lines. Melanoma Res. 1999;9:445-450. (Pubitemid 29494109)
14. Boyd SR, Tan DS, de Souza L, et al. Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. Br J Ophthalmol. 2002;86:440-447. (Pubitemid 34293295)
15. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342. (Pubitemid 38702844)
16. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550. (Pubitemid 44917502)
17. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-2676.
18. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23:792-799. (Pubitemid 46224178)
19. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434. (Pubitemid 36910021)
20. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevaci-zumab. J Surg Oncol. 2005;91:173-180. (Pubitemid 41254420)
21. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology. 2005;69(suppl 3):25-33. (Pubitemid 41680950)
22. Jaissle GB, Ulmer A, Henke-Fahle S, et al. Suppression of melanoma-associated neoangiogenesis by bevacizumab. Arch Dermatol. 2008;144:525-527. (Pubitemid 351581110)
23. Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 1998;58:808-814. (Pubitemid 28099496)
24. Sangfelt O, Erickson S, Castro J, et al. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene. 1999;18:2798-2810. (Pubitemid 29250869)
25. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992;326:1456-1463.
26. Raig ET, Jones NB, Varker KA, et al. VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. J Interferon Cytokine Res. 2008;28:553-561.
27. Pyrhonen S, Hahka-Kemppinen M, Muhonen T, et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer. 2002;95:2366-2372. (Pubitemid 35351144)
28. Nathan FE, Berd D, Sato T, et al. BOLD + interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Clin Cancer Res. 1997;16:201-208. (Pubitemid 27376581)
29. Kivela T, Suciu S, Hansson J, et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer. 2003;39:1115-1120. (Pubitemid 36555869)
30. Albert DM, Ryan LM, Borden EC. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol. 1996;114:107-108. (Pubitemid 26026209)
31. Notting IC, Missotten GS, Sijmons B, et al. Angiogenic profile of uveal melanoma. Curr Eye Res. 2006;31:775-785. (Pubitemid 44373549)
32. Sahin A, Kiratli H, Tezel GG, et al. Expression of vascular endothelial growth factor a, matrix metalloproteinase 9 and extravascular matrix patterns in iris and ciliary body melanomas. Ophthalmic Res. 2007;39:40-44. (Pubitemid 46095916)
33. Kvanta A, Steen B, Seregard S. Expression of vascular endothelial growth factor (VEGF) in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res. 1996;63:511-518. (Pubitemid 26420792)
34. Sheidow TG, Hooper PL, Crukley C, et al. Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. Br J Ophthalmol. 2000;84:750-756. (Pubitemid 30438555)
35. DeMoraes ED, Terai M, Aoyama T, et al. Serum vascular endothelium growth factor (VEGF) levels in patients with metastatic uveal melanoma and effect caused by hepatic artery embolization (HAE). ASCO Annual Meeting. 2002;abstr 1384.
36. Foss AJ, Alexander RA, Jefferies LW, et al. Microvessel count predicts survival in uveal melanoma. Cancer Res. 1996;56:2900-2903. (Pubitemid 26199727)
37. Makitie T, Summanen P, Tarkkanen A, et al. Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci. 1999;40:2471-2480. (Pubitemid 29455473)
38. Triozzi PL, Eng C, Singh AD. Targeted therapy for uveal melanoma. Cancer Treat Rev. 2008;34:247-258.
39. Yang H, Grossniklaus HE. Combined immunologic and anti-angiogenic therapy reduces hepatic micrometastases in a murine ocular melanoma model. Curr Eye Res. 2006;31:557-562. (Pubitemid 43884602)
40. Chan KR, Gundala S, Laudadio M, et al. A pilot study using sunitinib malate as therapy in patients with stage IV uveal melanoma. J Clin Oncol. 2008; 26.Abstract 9047.
41. Mouriaux F, Delcambre C, Durando X, et al. A Canceropole Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma. J Clin Oncol. 2008;26.Abstract 9061.
42. O'Day SJ. BEAM: A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paciltaxel in patients with previously untreated advanced melanoma. Paper presented at: ECCO/ESMO; September 23, 2009; Berlin, Germany.